SUP Inhibitors
Chemical inhibitors of the SUP protein function by interrupting various signaling pathways that are essential for the protein's role in cellular processes. Imatinib, Dasatinib, Nilotinib, Bosutinib, and Ponatinib are examples of such inhibitors, each targeting the BCR-ABL tyrosine kinase among others. By inhibiting this kinase, these chemicals effectively block the downstream signaling pathways that lead to cell proliferation and survival. For instance, Dasatinib extends its action to SRC family kinases, while Ponatinib is known for its broad-spectrum inhibition, including BCR-ABL. This blockade hampers the ability of the SUP protein to promote cell division and survival, as the signaling events that it depends upon are disrupted. The interruption of these pathways by the chemical inhibitors results in a diminishment of the SUP protein's function without affecting the protein's expression or structure directly.
In addition to BCR-ABL inhibitors, Gefitinib and Erlotinib specifically target the epidermal growth factor receptor (EGFR) tyrosine kinase. By selectively inhibiting EGFR, these inhibitors curtail the activation of various signaling cascades that SUP protein may rely on for its activity. Similarly, Lapatinib inhibits both the EGFR and HER2/neu tyrosine kinases, further reducing the signaling that is necessary for SUP protein activity. On a different front, chemicals like Sorafenib and Sunitinib target multiple kinases including VEGFR and PDGFR. These kinases are central to signaling pathways that regulate not just cell survival but also angiogenesis, which are essential for the functional activity of the SUP protein. Pazopanib and Vandetanib also contribute to the inhibition by targeting VEGFR, PDGFR, c-Kit, and RET-tyrosine kinase respectively, thus demonstrating the diversity of pathways that can influence the function of the SUP protein through their inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib targets the BCR-ABL tyrosine kinase, an essential component in the signaling pathways that lead to cell proliferation. Inhibition of this kinase results in the blockade of downstream pathways that promote cell division and survival, potentially inhibiting SUP by disrupting the proliferation of cells expressing this protein. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a multi-target tyrosine kinase inhibitor with activity against BCR-ABL and SRC family kinases. SUP activity is likely reliant on cellular signaling pathways mediated by these kinases, and dasatinib’s inhibition of these pathways can lead to decreased SUP protein activity by preventing signal transduction required for its function. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib is a selective inhibitor of the BCR-ABL tyrosine kinase. By selectively inhibiting this kinase, nilotinib disrupts the signaling cascade necessary for the proliferation and survival of cells that may be involved in the functional expression of SUP, leading to its functional inhibition. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
Ponatinib is a potent inhibitor of multiple tyrosine kinases, including BCR-ABL. It can obstruct the signaling pathways that SUP may rely on for its functional role in cells, thereby inhibiting the function of SUP by preventing necessary phosphorylation events. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the activation of several signaling cascades. By inhibiting EGFR, gefitinib can inhibit pathways that SUP may depend on for its functional role. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an inhibitor of the EGFR tyrosine kinase. Inhibition of EGFR can lead to a decrease in signaling pathways that are crucial for the function of SUP, resulting in the functional inhibition of SUP. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits EGFR and HER2/neu tyrosine kinases. As these kinases participate in critical signaling pathways, their inhibition by lapatinib could lead to reduced signaling necessary for SUP activity, achieving functional inhibition of SUP. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases, including VEGFR and PDGFR, which are key components of signaling pathways that regulate cell survival and angiogenesis. Inhibition of these pathways can suppress the functional role of SUP by blocking necessary cellular signals. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Sunitinib is a receptor tyrosine kinase inhibitor that targets PDGFR and VEGFR, among others. By inhibiting these kinases, sunitinib can decrease the signaling required for SUP function, indirectly leading to its functional inhibition. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib inhibits VEGFR, PDGFR, and c-Kit, which are involved in angiogenesis and cell proliferation. These pathways are essential for the functional activity of SUP, and their inhibition by pazopanib can lead to functional inhibition of SUP. | ||||||